QQQ   416.27 (-1.69%)
AAPL   164.62 (-1.45%)
MSFT   398.90 (-1.33%)
META   481.97 (-3.95%)
GOOGL   153.12 (-1.85%)
AMZN   174.66 (-2.54%)
TSLA   148.65 (-0.85%)
NVDA   810.00 (-4.34%)
AMD   148.61 (-4.17%)
NIO   3.82 (-4.50%)
BABA   68.57 (-0.45%)
T   16.33 (+0.00%)
F   12.08 (+0.17%)
MU   106.92 (-4.48%)
GE   148.19 (-3.11%)
CGC   8.02 (+2.43%)
DIS   111.78 (-0.58%)
AMC   3.26 (+11.64%)
PFE   25.77 (+1.50%)
PYPL   61.98 (-0.19%)
XOM   119.94 (+1.20%)
QQQ   416.27 (-1.69%)
AAPL   164.62 (-1.45%)
MSFT   398.90 (-1.33%)
META   481.97 (-3.95%)
GOOGL   153.12 (-1.85%)
AMZN   174.66 (-2.54%)
TSLA   148.65 (-0.85%)
NVDA   810.00 (-4.34%)
AMD   148.61 (-4.17%)
NIO   3.82 (-4.50%)
BABA   68.57 (-0.45%)
T   16.33 (+0.00%)
F   12.08 (+0.17%)
MU   106.92 (-4.48%)
GE   148.19 (-3.11%)
CGC   8.02 (+2.43%)
DIS   111.78 (-0.58%)
AMC   3.26 (+11.64%)
PFE   25.77 (+1.50%)
PYPL   61.98 (-0.19%)
XOM   119.94 (+1.20%)
QQQ   416.27 (-1.69%)
AAPL   164.62 (-1.45%)
MSFT   398.90 (-1.33%)
META   481.97 (-3.95%)
GOOGL   153.12 (-1.85%)
AMZN   174.66 (-2.54%)
TSLA   148.65 (-0.85%)
NVDA   810.00 (-4.34%)
AMD   148.61 (-4.17%)
NIO   3.82 (-4.50%)
BABA   68.57 (-0.45%)
T   16.33 (+0.00%)
F   12.08 (+0.17%)
MU   106.92 (-4.48%)
GE   148.19 (-3.11%)
CGC   8.02 (+2.43%)
DIS   111.78 (-0.58%)
AMC   3.26 (+11.64%)
PFE   25.77 (+1.50%)
PYPL   61.98 (-0.19%)
XOM   119.94 (+1.20%)
QQQ   416.27 (-1.69%)
AAPL   164.62 (-1.45%)
MSFT   398.90 (-1.33%)
META   481.97 (-3.95%)
GOOGL   153.12 (-1.85%)
AMZN   174.66 (-2.54%)
TSLA   148.65 (-0.85%)
NVDA   810.00 (-4.34%)
AMD   148.61 (-4.17%)
NIO   3.82 (-4.50%)
BABA   68.57 (-0.45%)
T   16.33 (+0.00%)
F   12.08 (+0.17%)
MU   106.92 (-4.48%)
GE   148.19 (-3.11%)
CGC   8.02 (+2.43%)
DIS   111.78 (-0.58%)
AMC   3.26 (+11.64%)
PFE   25.77 (+1.50%)
PYPL   61.98 (-0.19%)
XOM   119.94 (+1.20%)
Free Trial
NASDAQ:OBSV

ObsEva (OBSV) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)
Free OBSV Stock Alerts
$0.0050
0.00 (0.00%)
(As of 04/18/2024 ET)
Compare
Today's Range
$0.0020
▼
$0.0050
50-Day Range
$0.00
▼
$0.08
52-Week Range
$0.08
▼
$2.14
Volume
11,112 shs
Average Volume
8.94 million shs
Market Capitalization
$389,855.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock AnalysisChartCompetitorsFinancialsSEC FilingsSocial Media
OBSV stock logo

About ObsEva Stock (NASDAQ:OBSV)

ObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women's reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.

OBSV Stock Price History

OBSV Stock News Headlines

April 12, 2024 | americanbankingnews.com
ObsEva (NASDAQ:OBSV) Coverage Initiated by Analysts at StockNews.com
April 3, 2024 | globenewswire.com
ObsEva Announces Delisting from SIX Swiss Exchange and Exemption from Certain Obligations Associated with the Maintenance of Listin
April 19, 2024 | DTI (Ad)
Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
March 19, 2024 | globenewswire.com
ObsEva Announces Update on Board of Directors
February 28, 2024 | globenewswire.com
ObsEva Announces Wind-Down of Operations and Notifies SIX that it Will Lack the Resources to Establish Audited IFRS Financial Statements for 2023
February 26, 2024 | benzinga.com
ObsEva Stock (OTC:OBSEF) Dividends: History, Yield and Dates
November 11, 2023 | morningstar.com
ObsEva SA OBSN
November 11, 2023 | morningstar.com
ObsEva SA OBSEF
April 19, 2024 | DTI (Ad)
Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
June 18, 2023 | fool.com
ObsEva (NASDAQ: OBSV)
March 31, 2023 | finance.yahoo.com
ObsEva Files Year End 2022 Financial Statements
March 15, 2023 | finance.yahoo.com
ObsEva Announces Progress Towards its Plans to Consolidate Operations in Switzerland: Delisting of OBSV from The Nasdaq Stock Market effective March 23, 2023
March 13, 2023 | markets.businessinsider.com
ObsEva Names Fabien De Ladonchamps CEO, Ernest Loumaye Interim Chairman
March 13, 2023 | finance.yahoo.com
ObsEva Announces Update Towards its Strategic Reorganization to Consolidate Operations in Switzerland
March 3, 2023 | benzinga.com
Why Puma Biotechnology Shares Are Trading Lower By Over 15%? Here Are Other Stocks Moving In Friday's Mid-Day Session
March 3, 2023 | investorplace.com
Why Is ObsEva (OBSV) Stock Up 93% Today?
February 24, 2023 | investorplace.com
Why ObsEva (OBSV) Stock Is Down 36% Today
February 24, 2023 | finance.yahoo.com
ObsEva Announces Strategic Reorganization to Consolidate Operations in Switzerland
January 12, 2023 | uk.finance.yahoo.com
ObsEva Evidences Compliance with Nasdaq’s Stockholder’s Equity Rule and Announces Moratorium Dismissal Request Filing
December 19, 2022 | finance.yahoo.com
ObsEva Announces Dismissal of Moratorium Proceedings
December 14, 2022 | finance.yahoo.com
ObsEva Evidences Compliance with Nasdaq’s Stockholder’s Equity Rule and Announces Moratorium Dismissal Request Filing
December 1, 2022 | finance.yahoo.com
ObsEva SA (OBSV) Reports Q3 Loss, Lags Revenue Estimates
December 1, 2022 | finance.yahoo.com
ObsEva Announces Third Quarter 2022 Financial Results and Provides a Business Update
October 27, 2022 | finance.yahoo.com
ObsEva Announces Progress on Cost Reduction Initiatives and Stay of Moratorium Proceedings
October 16, 2022 | finance.yahoo.com
ObsEva SA (OBSV)
October 14, 2022 | markets.businessinsider.com
ObsEva : China Approves Yuyuan Bioscience's IND Application For Phase 1 Trial Of Nolasiban
October 13, 2022 | finance.yahoo.com
ObsEva Announces IND Approval for Yuyuan Bioscience’s Phase 1 Clinical Trial of Nolasiban in China - Yahoo Finance
See More Headlines
Receive OBSV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ObsEva and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/04/2021
Today
4/19/2024
Fiscal Year End
12/31/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:OBSV
CUSIP
N/A
CIK
1685316
Web
www.obseva.com
Phone
(122) 552-3840
Fax
N/A
Employees
48
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($0.92)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-58,380,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-416.36%
Return on Assets
-92.01%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.61
Quick Ratio
0.61

Sales & Book Value

Annual Sales
$20.11 million
Price / Sales
0.02
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.41 per share
Price / Book
0.01

Miscellaneous

Outstanding Shares
77,971,000
Free Float
66,743,000
Market Cap
$389,855.00
Optionable
Not Optionable
Beta
0.68
7 Stocks to Buy And Hold Forever Cover
7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • William M. Brown
    Chief Executive & Financial Officer
  • Elke Bestel
    VP, Head-Drug Safety & Pharmacovigilance
  • Katja Buhrer
    Chief Strategy Officer

Key Competitors

View All Competitors

OBSV Stock Analysis - Frequently Asked Questions

How have OBSV shares performed in 2024?

ObsEva's stock was trading at $0.0350 at the start of the year. Since then, OBSV shares have decreased by 85.7% and is now trading at $0.0050.
View the best growth stocks for 2024 here.

How were ObsEva's earnings last quarter?

ObsEva SA (NASDAQ:OBSV) announced its quarterly earnings data on Thursday, November, 4th. The company reported $0.01 earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.23.

What other stocks do shareholders of ObsEva own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ObsEva investors own include Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Dynavax Technologies (DVAX), Matinas BioPharma (MTNB), Trevena (TRVN), Zosano Pharma (ZSAN), Vaxart (VXRT), VBI Vaccines (VBIV), Bionano Genomics (BNGO) and ADMA Biologics (ADMA).

When did ObsEva IPO?

ObsEva (OBSV) raised $98 million in an initial public offering (IPO) on Thursday, January 26th 2017. The company issued 6,500,000 shares at $14.00-$16.00 per share. Credit Suisse, Jefferies and Leerink Partners acted as the underwriters for the IPO.

How do I buy shares of ObsEva?

Shares of OBSV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:OBSV) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
Biden’s $374B Giveaway Into This Sector
DTI
The #1 Crypto for 2024
InvestorPlace
He Is Giving Away Bitcoin
Crypto Swap Profits
Urgent alert: open this for a huge profit potential
Timothy Sykes
How Biden has already won 2024
Porter & Company
Top 5 AI Stocks to Buy for 2024
Market Moving Trends
My biggest AI fear
Paradigm Press
Options trading has suddenly become more reliable.
Eagle Publishing